Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Lindex’s customers donate 1.2 million euro to cancer research

With joined forces and great commitment, Lindex has together with its customers raised 1.2 million euro to cancer research.    “Thanks to the fantastic commitment of our employees and customers, we show once again that when we unite our efforts we can make a difference. It feels important that we together can contribute to cancer research so more people can survive and less people are affected by cancer”, says Susanne Ehnbåge, Lindex CEO. During the first weekend in October, Lindex donated 10 percent of the sales on all 18 markets and on lindex.com to cancer research. Lindex

Peab refurbishes the port in Köping

Peab has been commissioned to dredge Köping Port and then handle the dredged material. The customer is Köping Municipality and the contract is worth SEK 170 million.The project entails dredging up an area of around 4.5 kilometers on the outer edge of the port area in Köping. The project also includes dredging three other areas in the shipping lane. This will be done primarily to widen and ensure the proper depth along the shipping lane’s outer edges. It will generate a total of around 250,000 m2 dredged material. The polluted dredged material will be encapsulated so that it can then be

Notification of Extraordinary General Meeting in DNB ASA

Shareholders in DNB ASA are invited to attend the Extraordinary General Meeting to be held on Monday 30 November 2020 at 15:00.  Due to the corona situation, the Extraordinary General Meeting will be held digitally, using electronic voting.  Agenda: Proposals to merge with DNB Bank ASA, authorisation to the Board of Directors to decide a dividend for 2019 of up to NOK 9 per share, and authorisation to the Board of Directors to buy back shares. The notice of the Extraordinary General Meeting is attached.  Company information This information is subject to the disclosure

Prebona proves unique, long-term effect against COVID-19/SARS CoV-2

Independent test-institutes have confirmed that Prebona Disinfect is extremely effective against the coronavirus - SARS CoV-2, COVID-19. The tests, conducted on textiles, shows that before and even after 10 machine washes, Prebona Disinfect still eliminates 99,99% of virus particles after 60 minutes. 99% of the virus particles are eliminated after three minutes, and 99,99% after 60 minutes. All tests have been conducted in accordance with the global standard ISO 18184:2019 - These are truly excellent results, verifying the strength in our patented technology and also proving a

Senzime’s Interim report January – September 2020

Press release: Uppsala, November 6, 2020. Senzime AB’s (publ) Interim report for January – September 2020 is now available on the company’s website  www.senzime.comFinancial information for the third quarter 2020 · Net sales amounts to KSEK 2,096 (2,420) · Income after financial items amounts to KSEK -11,787 (-7,473) · Earnings per share amounts to SEK -0.20 (-0.14) Financial information for January-September 2020 · Net sales amounts to KSEK 5,843 (4,023) · Income after financial items amounts to KSEK -33,420 (-24,650) · Earnings per share amounts to SEK -0.58 (-0.

Last day of trading in paid subscribed units (Sw. BTU)

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, November 6, 2020 – Last day of trading in subscribed paid units (“BTU”) in ExpreS[2]ion Biotech Holding AB (publ) (“ExpreS[2]ion” or the “Company”) will be November 10, 2020 and stop day will be on November 12, 2020.

Invitation to Presentation of Immunovia´s Interim Report January – September 2020 on November 12, 2020

LUND (SWEDEN) – Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, November 12, 2020 at 16:30 CET. Immunovia will publish the company’s interim report on November 12, 2020 at 16:00 CET. Patrik Dahlen, CEO will present Immunovia and comment on the interim report for the period January – September 2020 followed by a Q&A session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator: Conference Call Sweden: +46 (0) 8 50520424 United

Rejlers wins framework agreement with FMV through NESP

Through its holding in NESP, Rejlers is entering into a new framework agreement with FMV (Swedish Defence Materiel Administration) concerning consultancy services within Integrated Logistics Support (ILS). The agreement runs for up to seven years and has provision for the Swedish Armed Forces to place suborders under the agreement.The new framework agreement with FMV covers consulting services within Integrated Logistics Support (ILS), which is a management process that supports development work in order to dimension and optimise maintenance systems based on requirements regarding

Interim Report April – September 2020

Another quarter with more then 30 percent growthCEO’s comments The second quarter of 2020/21 was another quarter with good growth for EQL Pharma. Sales for the quarter amounted to SEK 24.2 million, an increase of 36%. During the quarter, an order for healthcare consumables, totalling SEK 8 million, was received from a Hospital region. Around 3 MSEK of this order was invoiced during the quarter and the remaining part will be invoiced during the third quarter. The corona epidemic has had a minor impact on our company, where some products sell more than usual due to stock-outs for our

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or “the Company”) has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants (“Units”) with preferential rights for existing shareholders (the “Rights Issue”) of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the “Extraordinary General Meeting”). The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate

Brilinta approved in the US in stroke

6 November 2020 07:00 GMT Brilinta approved in the US to reduce the risk of stroke in patientswith an acute ischaemic stroke or high-risk transient ischaemic attack New indication expands use of Brilinta beyond cardiovascular disease to patients with mild-to-moderate stroke AstraZeneca's Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack (TIA). The approval by the

Moberg Pharma intends to distribute and separately list BupiZenge[®] (BUPI)

The Board of Directors of Moberg Pharma AB (OMX: MOB) today announces its intention to distribute the operations of BupiZenge[®] (BUPI) to the shareholders of Moberg Pharma by distributing 90 percent of the shares in a subsidiary (name to be changed to OncoZenge AB) through a so-called Lex ASEA distribution, and convenes an extraordinary general meeting to resolve accordingly. The business consists of developing the BUPI project under the brand name BupiZenge[®] for treatment of oral mucositis. Moberg Pharma estimates the capital requirement to take BupiZenge[®] through phase 3 at SEK 60

Interim report 1 January – 30 September 2020

third QUARTER (1 July – 30 September 2020) · Net sales for the quarter amounted to MSEK 24 (58). · Operating profit/loss before depreciation and amortisation (EBITDA) totalled MSEK 0 (21). · Operating profit/loss (EBIT) was MSEK -16 (2). · Profit/loss before tax amounted to MSEK -32 (-16). · Profit/loss after tax totalled MSEK -32 (-16), corresponding to SEK -0.93 (-0.48) per share before and after dilution. · Operating cash flow was MSEK 49 (-4). · Production from Own wind power operations was 68 GWh (69). · Average income from Own wind power operations was SEK

AcadeMedia strengthen its position through acquisition of Swedish Education Group for SEK 185 million

AcadeMedia has today entered into an agreement to acquire all shares in RE Skolor AB, the ultimate owner of Swedish Education Group AB. The acquisition includes operations in compulsory school, upper secondary school, and higher vocational education. The acquisition complements AcadeMedia’s existing business and strengthen our position in the growing markets of upper secondary school and adult education. The Swedish Education Group AB had a turnover in 2019/20 of approximately SEK 360 million and EBITDA of approximately SEK 35 million. The transaction has a cash and debt-free value (

Q3 and YTD report January – September 2020

Restructuring of Greek transaction resulted in accelerated collections and confirms credit quality in challenging marketHighlights third quarter 2020 · Net collections increased by 282% to EUR 63.1M (16.5) · Cash EBITDA increased by 353% to EUR 59.3M (13.1) · Net profit for the period of EUR 5.2M (loss of 1.5) · Cash on hand at the end of September 2020 was EUR 52M (12 at December 2019) · Greek restructuring resulted in accelerated collections of approximately EUR 55M · Written procedure completed with certain amendments to the terms and conditions of the DDM Debt AB up

Q3 and YTD report January – September 2020

Restructuring of Greek transaction resulted in accelerated collections and confirms credit quality in challenging marketHighlights third quarter 2020 · Net collections increased by 292% to EUR 62.1M (15.8) · Cash EBITDA increased by 330% to EUR 58.6M (13.6) · Net profit for the period of EUR 5.1M (loss of 1.2) · Cash on hand at the end of September 2020 was EUR 51M (11 at December 2019) · Greek restructuring resulted in accelerated collections of approximately EUR 55M · Written procedure completed with certain amendments to the terms and conditions of the up to EUR 160M

Humana reports third quarter 2020 results

A stable quarter with good news for personal assistanceThird quarter, July-September 2020 · Operating revenue was SEK 1,931m (1,928), which is in line with the previous year. Organic growth was 2.2%. · Operating profit was SEK 172m (176), a decrease of 3 %. Adjusted operating profit amounted to SEK 172m (172), which is in line with the previous year. · Net profit after tax for the period amounted to SEK 109m (128). · Basic and diluted earnings per share for the period amounted to SEK 2.05 (2.42). · Operating cash flow amounted to SEK 146m (206).  Interim period, January-

Invitation to a press conference: Kamux Corporation’s Interim Report for January—September 2020

Kamux Corporation     Investor News      6 November at 9:00 Invitation to a press conference: Kamux Corporation’s Interim Report for January—September 2020 Kamux Corporation will publish its Interim Report for January—September 2020 on Friday, 13 November, 2020 at about 9:00 a.m. Kamux will hold an Interim Report press conference and webcast for media and analysts on Friday, 13 November, 2020 at Hotel Kämp, Symposion meeting room (address Pohjoisesplanadi 29, Helsinki) at 11:00 (EET) in Finnish and then in English at around 11:45 (EET). You can follow the press conference

Navamedic ASA: Q3 2020 financial results

Oslo, 6 November 2020 – Navamedic ASA (OSE: NAVA) grew revenues by 16% in the third quarter of 2020 compared to the same quarter last year. The company reported revenues of NOK 56.8 million in the third quarter of 2020 with an EBITDA of NOK 3.8 million, driven by both new products and underlying growth. Navamedic will launch products in at least one country in each launch window going forward, and targets 20% annual growth from 2021. The company reiterates its mid- to long-term ambition of building a NOK 500 million company.“In the third quarter of 2020, we delivered strong growth driven by

Paulig achieves carbon neutral certification for its Vuosaari roastery

Paulig has taken a step forward in implementing its sustainability programme and achieved CarbonNeutral® building certification for its Vuosaari coffee roastery. The roastery has become Paulig’s first certified carbon neutral production site. The roastery building emissions have been reduced by 98% since 2014, and the remaining emissions have been offset through carbon finance projects. Paulig’s ambition is to reduce the greenhouse gas emissions from its own operations by 80% by 2030, and the plan is to make all of its production sites carbon neutral by the end of 2023.   “Paulig

Sveafastigheter Bostad becomes part of SBB, contributes 6,000 apartments in Greater Stockholm - SBB also makes a directed new share issue of 44.5 million Class B shares at a price of SEK 31.10

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) acquires 100 percent of the shares in Sveafastigheter Bostad (“Sveafastigheter”) for a purchase price of SEK 2,770 million. The transaction is financed in half through an issue of 44,533,762 Class B shares at a subscription price of SEK 31.10 per share, and the remaining part is financed by SBB realising certain financial assets. SBB already today owns, including ongoing projects, approximately 2,000 apartments in Greater Stockholm and with this acquisition the portfolio grows to approximately 8,000 apartments. All in all, this makes SBB a

Interim report July-September 2020

Gothenburg, November 6, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2020.Important events during the third quarter · In July, Vicore completed a directed share issue resulting in proceeds of 185 MSEK beforetransaction costs. · In July, Vicore announced that the first patient with COVID-19 had been dosed in the ATTRACT study in India. · In August, Vicore announced that the study with VP01 in patients with systemic sclerosis had restarted after the pause caused by the COVID-19 pandemic. · In September, Vicore announced that

Tradedoubler Interim Report January-September 2020

The third quarter July - September 2020 · Net sales amounted to SEK 285 M (280) an increase of 2% or 5% adjusted for changes in exchange rates compared to the same period last year. · Gross profit was SEK 59 M (62), a decrease of -4% and -1% adjusted for changes in exchange rates. Gross margin was 20.7% (22.0). · Operating costs excluding depreciation and change related items were SEK 42M (48), a decrease of -14% or -10% adjusted for changes in exchange rates. · EBITDA amounted to SEK 16 M (12). Adjusted for change related items, EBITDA was SEK 17 M (13). · Capitalised

Bambuser AB publishes quarterly statement for Q3 2020

Net sales had an accelerated growth of +1486% during the third quarter compared to the prior year. Bambuser experienced a continued increasing global demand for its Live Video Shopping technology. The Company's quarterly statement for the third quarter of 2020 has now been published and can be found at bambuser.com/ir. Bambuser continued to benefit from increased customer demand for Live Video Shopping in Q3. That pace is accelerating as retailers adapt their holiday-season strategies amid the ongoing pandemic. As previously reported, all major customer agreements (Enterprise) are

There are no items matching the current filter
There are no more items matching the current filter
Back to top